|
[1]
|
Zhu N, Zhang DY, Wang WL, Li XW, Yang B, Song JD, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382(8):727 − 33. http://dx.doi.org/10.1056/NEJMoa2001017CrossRef
|
|
[2]
|
World Health Organization. Coronavirus disease (COVID-2019) situation reports. https://wwwwhoint/emergencies/diseases/novelcoronavirus-2019/situation-reports. [2022-2-15].https://wwwwhoint/emergencies/diseases/novelcoronavirus-2019/situation-reports |
|
[3]
|
Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature 2021;600(7887):21. http://dx.doi.org/10.1038/d41586-021-03552-wCrossRef
|
|
[4]
|
Lazear HM, Schoggins JW, Diamond MS. Shared and distinct functions of type I and type III interferons. Immunity 2019;50(4):907 − 23. http://dx.doi.org/10.1016/j.immuni.2019.03.025CrossRef
|
|
[5]
|
Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 2020;179:104811. http://dx.doi.org/10.1016/j.antiviral.2020.104811CrossRef
|
|
[6]
|
Li M, Rao CM, Pei DN, Wang L, Li YN, Gao K, et al. Novaferon, a novel recombinant protein produced by DNA-shuffling of IFN-α, shows antitumor effect in vitro and in vivo. Cancer Cell Int 2014;14:8. http://dx.doi.org/10.1186/1475-2867-14-8CrossRef
|
|
[7]
|
Zheng F, Zhou YW, Zhou ZG, Ye F, Huang BY, Huang YX, et al. SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: a randomized, open-label, parallel-group trial. Int J Infect Dis 2020;99:84 − 91. http://dx.doi.org/10.1016/j.ijid.2020.07.053CrossRef
|
|
[8]
|
Yao XT, Ye F, Zhang M, Cui C, Huang BY, Niu PH, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71(15):732 − 9. http://dx.doi.org/10.1093/cid/ciaa237CrossRef
|
|
[9]
|
Lokugamage KG, Hage A, De Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, et al. Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV. J Virol 2020;94(23):e01410 − 20. http://dx.doi.org/10.1128/JVI.01410-20CrossRef
|
|
[10]
|
Luckhardt TR, Coomes SM, Trujillo G, Stoolman JS, Vannella KM, Bhan U, et al. TLR9-induced interferon β is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 2011;4:18. http://dx.doi.org/10.1186/1755-1536-4-18CrossRef
|